This compound is primarily used in cancer research and therapy due to its ability to inhibit EGFR, ErbB-2, and ErbB-4 receptors, which are often overexpressed in various cancers. By targeting these receptors, it helps in blocking the signaling pathways that promote tumor growth and survival. It is particularly studied for its potential in treating breast, lung, and colorectal cancers. Additionally, it may enhance the efficacy of other cancer treatments when used in combination therapies. Its role in preclinical studies is crucial for understanding its mechanism of action and optimizing its use in clinical settings.